Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company focused on Alzheimer's disease treatments, announced it will release its first quarter 2026 financial results on May 12, 2026. The company will host a live conference call and webcast at 8:00 a.m. ET to provide updates on its business and financial status. Acumen is advancing its lead drug candidate, sabirnetug (ACU193), in a Phase 2 clinical trial for early symptomatic Alzheimer's disease, with positive Phase 1 results previously reported. Investors and interested parties can register to participate in the webcast, which will also be archived on the company's website.
The 32nd Global Family Office Investment Summit in Lake Como gathered over 200 family office leaders, investors, and entrepreneurs from 27 countries to discuss emerging trends in AI, private equity, healthcare innovation, and global investment opport...
Bath & Body Works introduced Fruit Fusion, a new body care franchise featuring fruit-inspired scents and hydrating formulas, available in the U.S. and Canada starting July 6, 2026. Actress Hilary Duff serves as the brand ambassador and creative partn...
Prestige Consumer Healthcare completed the acquisition of Australian therapeutic skin care company LaCorium Health for approximately $150 million in cash on July 1, 2026. LaCorium, known for brands like Dermal Therapy and Flexitol, generates about $4...
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...
Diginex Limited has agreed with Resulticks to extend the deadline for their acquisition deal to July 31, 2026, after securing firm funding intent from private investors. The company does not plan to seek public funding and expects this to be the fina...
